As of 2026-09-17, the Relative Valuation of Arrowhead Pharmaceuticals Inc (ARWR) is (19.33) USD. This relative valuation is based on P/E multiples. With the latest stock price at 65.79 USD, the upside of Arrowhead Pharmaceuticals Inc based on Relative Valuation is -129.4%.
The range of the Relative Valuation is (46.11) - 13.90 USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 20.3x - 26.2x | 22.2x |
| Forward P/E multiples | 24.0x - 28.8x | 24.6x |
| Fair Price | (46.11) - 13.90 | (19.33) |
| Upside | -170.1% - -78.9% | -129.4% |
| Date | P/E |
| 2026-09-16 | -28.96 |
| 2026-09-15 | -31.11 |
| 2026-09-14 | -35.52 |
| 2026-09-11 | -36.48 |
| 2026-09-10 | -36.44 |
| 2026-09-09 | -36.38 |
| 2026-09-08 | -37.47 |
| 2026-09-04 | -38.01 |
| 2026-09-03 | -38.08 |
| 2026-09-02 | -37.58 |
| 2026-09-01 | -36.43 |
| 2026-08-31 | -36.27 |
| 2026-08-28 | -37.38 |
| 2026-08-27 | -39.00 |
| 2026-08-26 | -39.24 |
| 2026-08-25 | -39.13 |
| 2026-08-24 | -38.18 |
| 2026-08-21 | -38.35 |
| 2026-08-20 | -38.51 |
| 2026-08-19 | -39.36 |
| 2026-08-18 | -38.70 |
| 2026-08-17 | -39.05 |
| 2026-08-14 | -38.14 |
| 2026-08-13 | -37.68 |
| 2026-08-12 | -38.41 |
| 2026-08-11 | -39.29 |
| 2026-08-10 | -38.89 |
| 2026-08-07 | -38.59 |
| 2026-08-06 | -37.79 |
| 2026-08-05 | -38.26 |
| 2026-08-04 | -39.44 |
| 2026-08-03 | -37.87 |
| 2026-07-31 | -37.27 |
| 2026-07-30 | -38.44 |
| 2026-07-29 | -37.96 |
| 2026-07-28 | -37.77 |
| 2026-07-27 | -37.66 |
| 2026-07-24 | -37.69 |
| 2026-07-23 | -38.21 |
| 2026-07-22 | -39.05 |
| 2026-07-21 | -32.81 |
| 2026-07-20 | -31.54 |
| 2026-07-17 | -32.71 |
| 2026-07-16 | -31.42 |
| 2026-07-15 | -31.62 |
| 2026-07-14 | -31.66 |
| 2026-07-13 | -32.63 |
| 2026-07-10 | -33.64 |
| 2026-07-09 | -36.98 |
| 2026-07-08 | -37.75 |